M. Cavo, E. Terpos, C. Nanni, P. Moreau, S. Lentzsch et al., Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group, Lancet Oncol, vol.18, p.1384, 2017.

P. Moreau, M. Attal, D. Caillot, M. Macro, L. Karlin et al., Prospective Evaluation of Magnetic Resonance Imaging and [ 18 F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study, J. Clin. Oncol, vol.35, pp.2911-2918, 2017.

R. A. Kyle and S. V. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, vol.23, pp.3-9, 2009.

S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014.

S. K. Kumar, V. Rajkumar, R. A. Kyle, M. Van-duin, P. Sonneveld et al., Multiple myeloma, Nat. Rev. Dis. Primers, vol.3, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01813384

L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko et al., Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat. Commun, vol.8, 2017.

L. Rasche, E. J. Angtuaco, T. L. Alpe, G. H. Gershner, J. E. Mcdonald et al., The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma, Blood, vol.132, pp.59-66, 2018.

T. B. Bartel, J. Haessler, T. L. Brown, J. D. Shaughnessy, F. Van-rhee et al., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, pp.2068-2076, 2009.

E. Zamagni, F. Patriarca, C. Nanni, B. Zannetti, E. Englaro et al., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, Blood, vol.118, pp.5989-5995, 2011.

E. Zamagni, C. Nanni, F. Gay, A. Pezzi, F. Patriarca et al., 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, Leukemia, vol.30, pp.417-422, 2016.

Y. Lu, J. Chen, W. Lin, J. Liang, H. Wang et al., FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-analysis, Clin. Nucl. Med, vol.37, pp.833-837, 2012.

W. Weng, M. Dong, J. Zhang, J. Yang, Q. Xu et al., A Systematic Review of MRI, Scintigraphy, FDG-PET and PET/CT for Diagnosis of Multiple Myeloma Related Bone Disease-Which is Best?, Asian Pacific J. Cancer Prev, vol.15, pp.9879-9884, 2014.

E. Zamagni, C. Nanni, F. Patriarca, E. Englaro, P. Castellucci et al., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma, Haematologica, vol.92, pp.50-55, 2007.

R. Fonti, L. Pace, C. Cerchione, L. Catalano, B. Salvatore et al., Del Vecchio, S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study, Clin. Nucl. Med, vol.40, pp.303-308, 2015.

R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto et al., 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma, J. Nucl. Med, vol.49, pp.195-200, 2008.

L. Rasche, E. Angtuaco, J. E. Mcdonald, A. Buros, C. Stein et al., Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma, vol.130, pp.30-34, 2017.

Y. Abe, S. Ikeda, A. Kitadate, K. Narita, H. Kobayashi et al., Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.1345-1350, 2019.

P. Moreau, M. Attal, C. Hulin, B. Arnulf, K. Belhadj et al., Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study, Lancet, vol.394, pp.29-38, 2019.

P. Moreau, S. Zweegman, A. Perrot, C. Hulin, D. Caillot et al., Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study, Blood, vol.134, 2019.

R. C. Walker, T. L. Brown, L. B. Jones-jackson, L. De-blanche, and T. Bartel, Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias, J. Nucl. Med, vol.53, pp.1091-1101, 2012.

Y. Abe, K. Narita, H. Kobayashi, A. Kitadate, M. Takeuchi et al., Medullary Abnormalities in Appendicular Skeletons Detected With 18 F-FDG PET/CT Predict an Unfavorable Prognosis in Newly Diagnosed Multiple Myeloma Patients With High-Risk Factors, Am. J. Roentgenol, vol.213, pp.918-924, 2019.

T. Carlier and C. Bailly, State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front, vol.2, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817854

R. Haznedar, S. Z. Ak?, Ö. U. Akdemir, Z. N. Özkurt, Ö. Çeneli et al., Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma, Eur. J. Nucl. Med. Mol. Imaging, vol.38, pp.1046-1053, 2011.

R. Fonti, M. Larobina, S. Del-vecchio, S. De-luca, R. Fabbricini et al., Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma, J. Nucl. Med, vol.53, pp.1829-1835, 2012.

J. E. Mcdonald, M. M. Kessler, M. W. Gardner, A. F. Buros, J. A. Ntambi et al., Assessment of Total Lesion Glycolysis by 18 F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma, Clin. Cancer Res, vol.23, 1981.

R. Fonti, S. Pellegrino, L. Catalano, F. Pane, S. Del-vecchio et al., Visual and volumetric parameters by 18F-FDG-PET/CT: A head to head comparison for the prediction of outcome in patients with multiple myeloma, Ann. Hematol, vol.2020, pp.127-135

L. Morvan, T. Carlier, B. Jamet, C. Bailly, C. Bodet-milin et al., Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis, Int. J, vol.2020, pp.129-139
URL : https://hal.archives-ouvertes.fr/hal-02172435

J. Hillengass, S. Usmani, S. V. Rajkumar, B. G. Durie, M. Mateos et al., International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders, Lancet Oncol, vol.20, pp.302-312, 2019.

B. Siontis, S. Kumar, A. Dispenzieri, M. T. Drake, M. Q. Lacy et al., Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy, Blood Cancer J, vol.5, 2015.

L. A. Moulopoulos, V. Koutoulidis, J. Hillengass, E. Zamagni, J. D. Aquerreta et al., Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: A report of the IMWG Bone Working Group, Blood Cancer J, vol.8, p.95, 2018.

P. Salaun, T. Gastinne, E. Frampas, C. Bodet-milin, P. Moreau et al., FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma, Haematologica, vol.93, pp.1269-1271, 2008.

G. Fouquet, S. Guidez, C. Herbaux, Z. Van-de-wyngaert, S. Bonnet et al., Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma, Clin. Cancer Res, vol.20, pp.3254-3260, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01064578

C. Lapa, K. Lückerath, U. Malzahn, S. Samnick, H. Einsele et al., FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation, Oncotarget, vol.5, pp.7381-7391, 2014.

B. Jamet, C. Bailly, T. Carlier, L. Planche, C. Touzeau et al., Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients, Leuk. Lymphoma, vol.60, pp.222-225, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01823037

N. Hovhannisyan, M. Dhilly, M. Fidalgo, F. Fillesoye, S. Guillouet et al., 18F]Fludarabine-PET in a murine model of multiple myeloma, PLoS ONE, vol.12, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01575068

T. R. Ullah, The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond, J. Bone Oncol, vol.17, 2019.

A. Peled, S. Klein, K. Beider, J. A. Burger, and M. Abraham, Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies, Cytokine, vol.109, pp.11-16, 2018.

C. Lapa, M. Schreder, A. Schirbel, S. Samnick, K. M. Kortüm et al., 68 Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma-Comparison to [ 18 F]FDG and laboratory values, vol.7, pp.205-212, 2017.

C. Lapa, K. Herrmann, A. Schirbel, H. Hänscheid, K. Lückerath et al., CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma, vol.7, pp.1589-1597, 2017.

A. R. Haug, A. Leisser, W. Wadsak, M. Mitterhauser, S. Pfaff et al., Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [ 68 Ga]Ga-Pentixafor-PET/MRI. Theranostics, vol.9, pp.3653-3658, 2019.

Y. Luo, X. Cao, Q. Pan, J. Li, J. Feng et al., 68 Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18 F-FDG PET/CT, J. Nucl. Med, vol.60, pp.1724-1729, 2019.

S. Ahn, S. Y. Kwon, S. Jung, J. Ahn, S. W. Yoo et al., Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma, Clin. Nucl. Med, vol.43, pp.259-264, 2018.

C. Lapa, S. Knop, M. Schreder, M. Rudelius, M. Knott et al., 11 C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement, Theranostics, vol.6, pp.254-261, 2016.

M. I. Morales-lozano, O. Viering, S. Samnick, P. Rodriguez-otero, A. K. Buck et al., FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers, Cancers, vol.12, 1042.

S. N. Shah and J. D. Oldan, PET/MR Imaging of Multiple Myeloma, Magn. Reson. Imaging Clin. N. Am, vol.25, pp.351-365, 2017.